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TDR recently published an historical
review of three decades of the organization’s
activities since its establishment as the
Special Programme for Research and
Training in Tropical Diseases in 1978 [1].
There have been four external reviews of
TDR during this time, each followed by
reorganization,institutional-fine-tuning,and
adaptation to changing circumstances in the
world of science and research. Independent
external review has thus been integral to
TDR, supporting its mission as a steward in
forwarding public research interests, most
particularly research on infectious diseases
affecting the world’s poorest and most
disadvantaged populations.
The Fourth External Review [2], con-
ducted between February 2005 and May
2006, was thus received as a core element
of TDR’s process of periodic institutional
evaluation and adjustment. The findings
of the review are summarized in an article
in this issue of PLoS Neglected Tropical
Diseases [3]. Ultimately, the review con-
tributed to key elements of a new TDR
Ten Year Strategy [4] and business plan
[5] approved by TDR’s Joint Coordinat-
ing Board in June 2007 and endorsed by
the World Health Organization (WHO)
(see Box 1). That strategy is now in the first
stages of implementation.
TDR’s New Business Plan, in
Light of the 2006 External
Review
The Fourth External Review called for
an increased emphasis on ‘‘needy popula-
tions’’ as compared to ‘‘neglected diseas-
es’’ and a move towards a more trans-
disciplinary view of health, defined by
social as well as biomedical determinants.
The new TDR vision statement (Box 1)
reflects this recommendation. In practice,
TDR is now less driven by the concept of a
disease portfolio and more driven by
infectious disease–related research needs
and TDR’s comparative advantage to
address those needs.
A diagrammatic representation of the
analysis and functional manifestation of the
new strategy is presented in Figure 1.
Figure 1A illustrates the concept of a
research continuum highlighting the cross-
cutting features required to sustain relevant
and high-quality research, namely knowl-
edge management leading to the concept of
stewardship, and capacity building leading
to the concept of empowerment. The gap
analysis identifies where TDR should place
special emphasis in its research, specifically
innovation for product development, inter-
vention research, and implementation re-
search for access to interventions.
Figure 1B illustrates how TDR’s func-
tions and business line research activities
map out against the research continuum.
Each of these activities is supported by an
expert scientific advisory committee. The
‘‘business line’’ approach facilitates focused
research efforts within a decentralized
management and administrative structure
that is responsive to change. Research
business lines may be closed down as goals
are reached or as activities are spun-off to
other organizations, or initiated as new
needs are identified through expert advice
and stakeholder consultation, e.g., through
its stewardship function, and endorsed
through governance decisions.
In addition to the functional priorities of
TDR discussed above, the Fourth Exter-
nal Review also made a number of
recommendations relating to broad issues
of governance, administration, and orga-
nization of the Programme. Before dis-
cussing those in more detail, we outline the
overall process of TDR’s strategy devel-
opment and the role played by the Fourth
External Review in that process.
Process of TDR’s Strategy
Development
The process of TDR’s strategy revision
was dependent on its governance struc-
ture. This is depicted in Figure 2 [6]. TDR
is governed by a Joint Coordinating Board
(JCB) consisting of representatives of 30
national governments, equally divided
between developed and developing coun-
tries, plus its four co-sponsoring agencies,
the United Nations Children’s Fund
(UNICEF), the United Nations Develop-
ment Programme (UNDP), the World
Bank, and WHO. Its meetings are open
to a wide range of observers that are
identified as TDR cooperating parties and
include representatives of additional na-
tional governments and representatives of
academic and non-governmental institu-
tions. TDR operates under the legal
auspices of WHO as its executing agency.
WHO is represented on the JCB through
a special programme coordinator, normal-
ly an Assistant Director General to whom
the Director of TDR reports. Two other
significant bodies are (i) the Scientific and
Technical Advisory Committee (STAC),
which meets once a year to technically
review the Programme and both advises
the Director and reports to the JCB; (ii) the
Standing Committee of the Joint Coordi-
nating Board, which meets several times a
year to monitor strategic and managerial
issues in between the annual JCB meet-
ings. The chairs of JCB and STAC also
attend this committee meeting together
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Theprocessoffeedinginthecommentsof
the Fourth External Review into the strategy
development process is detailed in Box 2.
Global Positioning of TDR: Role
of Governance, Management
and Administration
The first of the Fourth External Re-
view’s recommendations refers to the need
for ‘‘ALL stakeholders to support TDR to
evolve and grow to a renewed mandate
that addresses the very neglected diseases
and the health needs of the most needy
populations’’.
The revised TDR strategy and its
implementation seeks to earn such support
through being responsive to stakeholder
issues through its stewardship, empower-
ment, and research functions. TDR’s Joint
Coordinating Board has also instituted
several changes, with more under discus-
sion, to make TDR’s governance struc-
tures more responsive to its wider constit-
uencies, notably within disease-endemic
countries, to ensure that they play a
‘‘pivotal role’’ in TDR decision making.
For example, consideration is being given
to the participation of non-governmental
constituencies on the Joint Coordinating
Board. A useful summary of this discussion
can be found in summary conclusions and
recommendations number 53 to 60 of the
Joint Coordinating Board Meeting of June
2007 [8].
A frequent complaint of organizations
based at the UN relates to bureaucratic
administrative processes, and the Fourth
External Review expressed concern that
TDR was over-administered and under-
managed. The new management structure
that forms part of the TDR business plan
seeks to address this by decentralizing
managerial and administrative authority
within the Programme down to the level of
the business lines. This is being comple-
mented by a major initiative within WHO
to improve its management and adminis-
trative practices, which will be of further
benefit for TDR.
One of the recommendations from the
Fourth External Review that was not taken
up by TDR’s governing bodies was the
proposal to administratively decentralize its
activities to regional centers. Following
extensive discussion and debate, it was felt
that while functional decentralization was seen
as desirable, administrative decentralization
would be counterproductive. Rather than
making TDR more responsive to disease-
endemic countries, it was feared that such a
measure would increase costs and related
bureaucracy, draining off resources that
could otherwise be funnelled directly to
developing country institutions, expert
networks, and other groups.
Instead, key elements of the TDR
business plan further these same aims
without the creation of new TDR offices,
for example through 1) increased emphasis
on global and regional networks of experts
and stakeholders; 2) creation of thematic
and disease reference groups, to be hosted
by different countries; 3) reinforcing rela-
tionships with the regional and country
offices of WHO and other co-sponsoring
agencies; and 4) support for the recruit-
ment of individuals and consultants, based
in disease-endemic country institutions, to
facilitate TDR activities.
Assessment of the Past and
Looking Forward to the Future
TDR faced some serious issues at the
timeofthe FourthExternal Reviewandhas
responded to these through its new strategy
and business plan. However, it is worth
taking a deeper look at the extraordinary
changes that were happening in global
health research between 1999 and 2005
and the pressures these were placing on
TDR. Perhaps the biggest single area of
change was in the area of product devel-
opment.
TDR’s Third External Review in 1998
concluded that there was limited industry or
public sector engagement in product devel-
opmentforneglectedtropicaldiseases.TDR
was thus asked to scale up its activities in this
area and it responded. By the year 2000,
TDR had roughly 15 product development
activities underway, although many were
chronically under-funded. Recognition by
TDR’s own governance and management
that funding would be more effective
through scaled up, externally leveraged
and dedicated efforts led TDR to help
conceptualize, incubate, and formally part-
ner the establishment of several product
development partnerships, notably Medi-
cines for Malaria Venture (MMV) in 1999
and the Foundation for Innovative New
Diagnostics (FIND) in 2003. TDR also
significantly assisted in the development of
the Global Alliance for TB Drug Develop-
Box 1. TDR’s New Ten Year Strategy
Vision: To foster an effective global research effort on infectious diseases of poverty
in which disease-endemic countries play a pivotal role.
Key TDR Strategic Functions:
N Stewardship for research on infectious diseases of poor populations: as
facilitator and knowledge manager to support needs assessment, priority
setting, progress analysis, and advocacy, and to provide a neutral platform for
partners to discuss and harmonize their activities.
Top level objective is to bring about greater harmonization of global research
efforts.
N Empowerment of researchers and public health professionals from disease-
endemic countries, moving beyond traditional research training to build
leadership at individual, institutional, and national levels so countries can better
initiate and lead research activities, develop a stronger presence in international
health research, and effectively use research results to inform policy and
practice.
Top level objective is to promote disease-endemic country leadership in research.
N Research on neglected priority needs that are not adequately addressed by
other partners. This will focus on three research functions:
a) Foster innovation for product discovery and development,
b) Foster research on development and evaluation of interventions in real-life
settings,
c) Foster implementation research for access to interventions.
This strategic function will be managed through a limited number of well-defined
and coherent activities termed business lines.
Top level objective is to bring about enhanced access to superior interventions.
www.plosntds.org 2 November 2008 | Volume 2 | Issue 11 | e307Figure 1. Analysis Using Health Research Continuum. (A) Functional assessment of health research continuum and gaps (in red) that need to
be addressed. (B) Functional activities and business lines of new strategy mapped against the research continuum. Abbreviations: Grand Challenges,
Grand Challenges in Global Health; NIH, US National Institutes of Health; Trust, Wellcome Trust; EDCTP, European and Developing Countries Clinical
Trial Platform; MMV, Medicines for Malaria Venture; Microbicides, Alliance for Microbicide Development; DNDi, Drugs for Neglected Diseases Initiative;
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for Neglected Diseases Initiative (DNDi) in
2002. TDR currently manages only two
significant drug development projects. Some
of the projects that were transitioned from
TDR to product development partnerships
(PPPs) during this period are listed in Box 3.
Such was the success of these initiatives,
supported through new funding from both
governments and philanthropic founda-
tions such as the Bill & Melinda Gates
Foundation, that by the time the Fourth
External Review was issued, just eight
years later, the pendulum had swung
dramatically. Thus, a major conclusion
was that TDR should significantly reduce
the scope of its activities in these areas.
This kind of radical swing in focus
places great pressure on an organization in
terms of strategic direction, modes of
operation, staff competencies, and com-
mitment to different projects. Few organi-
zations in this field could have transitioned
so many of their own activities so quickly
to other organizations, as did TDR over
the past few years, in the name of
advancing the broader goals of tropical
disease research. The success of these
transitions is testimony, again, to the
inherent strengths and flexibility of TDR
as an organization. From 1999 to 2006,
TDR was also a partner in many research
and capacity-building achievements (see
Box 4); TDR progress reports covering
these years can be found at [9]. TDR
continued to generate through its funding
approximately 250 peer-reviewed articles
per year, with over 50% having a lead
author from a developing country institu-
tion, combined with support for individual
and institutional capacity strengthening.
We are not complacent about the issues
that still face TDR. However, because
TDR works through partners in a way that
promotes their achievements, the achieve-
ments of TDR as an organization are
often under-valued. TDR was judged by
the Fourth External Review to be moder-
ately successful from 1998 to 2005, largely
due to the reduced global significance of
the Programme with the arrival and
GATB, Global Alliance for TB Drug Development, IAVI, International AIDS Vaccine Initiative; FIND, Foundation for Innovative New Diagnostics; GAELF,
Global Alliance for the Elimination of Lymphatic Filariasis; Trachoma, International Trachoma Initiative; RBM, Roll Back Malaria partnership; StopTB,
Stop TB partnership; Global Fund, Global Fund to Fight AIDS, TB and Malaria; APOC, African Programme for Onchocerciasis Control. Image credit:
WHO/TDR.
doi:10.1371/journal.pntd.0000307.g001
Figure 2. TDR Governance Structure. Image credit: WHO/TDR.
doi:10.1371/journal.pntd.0000307.g002
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initiatives. Paradoxically, we believe that
when the history of this period is written,
and particularly when judged against its
budget, TDR’s role will be seen to have
been highly significant and successful in
terms of its public health impact.
The one constant in this world is
change. TDR, along with the rest of an
increasingly well-resourced and vibrant
health research community, needs to be
continuously open to further adaptation
and change. We need to manage such
change in a way that coherently and
sustainably advances a beneficial impact
on people struggling to meet their health
needs and the needs of their families and
communities in conditions of poverty.
TDR is already making an impact in
response to the gaps identified in the
analysis outlined in Figure 1. Its plans for
enhanced knowledge management and
stakeholder consultation are on track with
the recent launch of a new TropIKA web
portal (http://www.tropika.net/) to pro-
mote these activities [10]. Networked
initiatives with otherinstitutions topromote
disease-endemic country leadership in re-
search are being initiated. In the area of
translationresearch forproduct innovation,
TDR has closely liaised with the WHO-led
Intergovernmental Working Group on
Public Health, Innovation and Intellectual
Property [11], and TDR is establishing
partnership networks to stimulate work in
this area [12]. In the area of intervention
and implementation research, TDR is
spearheading new research processes that
have demonstrated the power of commu-
nity-directed interventions to address mul-
tiple diseases, including malaria, in an
integrated way [13] and are influencing
policy in Africa. TDR is also working with
the Global Fund to Fight AIDS, TB and
Malaria to promote frameworks for devel-
oping capacity for implementation and
operational research [14].
The new strategy leaves TDR well
placed to deal with future change.
It will achieve this if it remains true to its
vision statement, inspired by many of the
conclusions of the Fourth External Re-
view, that its role is ‘‘to foster an effective
global research effort on infectious diseases
of poverty in which disease-endemic
countries play a pivotal role’’.
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Box 3. Projects Transitioned to Product Development
Partnerships by TDR since 1999
TDR-initiated projects transferred to new PPPs have included the following:
MMV (1999 launch): Pyronaridine plus artesunate; chlorporguanil-dapsone
plus artesunate; dihydroartemisinin plus piperaquine; paediatric formulation of
Coartem; synthetic peroxide.
DNDi (2002 launch): Amodiaquine plus artesunate; mefloquine plus artesu-
nate.
FIND (2003 launch): Projects in TB and malaria.
Institute for OneWorld Health: Paromomycin for visceral leishmaniasis.
Box 4. TDR as a Partner in Research and Capacity Building,
1999–2006
N Registration of miltefosine for treatment of visceral leishmaniasis with the
Indian Council for Medical Research and Zentaris, leading to a political
commitment to eliminate the disease from the Indian sub-continent by 2015.
N Label extension of Coartem (artemether–lumefantrine) for use in small children
(5 kg), enabling its broader use, especially in Africa.
N Multi-country studies demonstrating the value of artemisinin-based combina-
tion therapy for malaria, leading to global policy recommendations.
N Network-based partnerships such as the Strategic Initiative for Developing
Capacity for Ethical Review and the Forum for African Medical Editors.
N Facilitation of the sequencing of the mosquito genome and facilitation of a
consortium for the sequencing of the tsetse fly genome.
Box 2. Process from Fourth External Review to New Strategy
Initiation of Fourth External Review at request of 2004 JCB Jan 2005
Comment on Preliminary Report of Fourth External Review by STAC Feb 2006
Comment on Preliminary Report of Fourth External Review
by Standing Committee
March 2006
Final Report of Fourth External review May 2006
JCB assessment of Fourth External Review and comments by STAC
and Standing Committee. Guidance provided on key directions
for future strategy
June 2006
Development of draft strategy document through external
consultation and interim technical review by STAC
Oct 2006
Special Stakeholder Consultation Meeting followed by Special
Meeting of JCB to review draft strategy. Modifications suggested
and request made for business plan to be developed
Oct 2006
Review of draft business plan by STAC Feb 2007
Review of further draft business plan by Standing Committee March 2007
Review and final endorsement of business plan by JCB [7] June 2007
Formal initiation of strategy and business plan implementation
within WHO
Jan 2008
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